Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap
Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap Yahoo Finance
Covered in this story
What has happened since
- Amgen is down 3.0% since this was published, 52 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
- UBS: $408 → $440 by Aug 2027 · Buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.